HOME >> BIOLOGY >> NEWS
$18 million bioinformatics center to become weapon against deadly diseases

A computer database designed to help biomedical scientists identify and exploit the weak spots in scores of deadly microorganisms will be established with an $18 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

Overseeing the effort will be the Computation Institute, a joint effort between the University of Chicago and Argonne National Laboratory, and the Fellowship for Interpretation of Genomes, a non-profit organization specializing in bioinformatics tool development and comparative genomics research.

They will use the funds to set up a National Microbial Pathogen Data Resource Center to help scientists to accelerate their research into the biology and evolution of deadly microorganisms and develop methods for their control.

The new center will provide infectious disease researchers a single Web-based entry point to all relevant organism-related data necessary for their advanced research. The genomes (genetic maps) of hundreds and eventually thousands of microorganisms will be available for integrated analysis.

"The center will directly support the national effort to develop new vaccines, therapeutics and diagnostics for emerging and re-emerging infectious diseases," said Computation Institute Director Rick Stevens, who will co- direct the center.

"A central goal of the center will be to gather all existing data on these organisms and embed this data within a framework that will support researchers in their efforts to understand them," said center Co-Director Ross Overbeek.

Working together at the center will be a team of experts in biology, biophysics, microbiology, computer science and bioinformatics (the application of mathematics and computer science to biological problems).

Stevens, a Professor in Computer Science at the University of Chicago and Director of the Mathematics and Computer Science Division at Argonne, specia
'"/>

Contact: Steve Koppes
skoppes@uchicago.edu
773-702-8366
University of Chicago
3-Sep-2004


Page: 1 2 3

Related biology news :

1. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
2. Half-million dollar landmark achieved for the Methuselah Mouse Prize
3. HHMI, NIBIB/NIH to invest up to $35 million in interdisciplinary Ph.D. programs
4. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
5. $2.7 million grant to support creation of virtual zebrafish atlas
6. Tufts University establishes $4 million dollar tissue engineering resource center
7. PNNL lands $10.3 million NIH biodefense contract to unlock proteomes of salmonella and pox
8. Pacific Northwest National Laboratory gets $10 million from NIH to build virtual lung
9. University of Pittsburgh receives $10 million grant for head and neck cancer
10. UCR earns $1.5 million grant to examine how engineered crop genes stray
11. LSU Vet School receives $9.9 million for infectious disease research

Post Your Comments:
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... Drug Administration (CFDA) has approved the Company,s application to ... clear cell carcinoma (OCCC) patients for its proprietary drug ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: